A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)

Plain-language summary

This study evaluates the efficacy and safety of glutamine and creatine monohydrate in Duchenne Muscular Dystrophy (DMD). It included ambulant children aged 5-10 with an established DMD diagnosis. It was a Phase 3 study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 3

Status

Completed

Sponsor

National Center for Research Resources (NCRR)

Intervention

glutamine, creatine monohydrate

Countries

United States

Related genes

Locations

• St Louis, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Ambulant children age 5-10 years with an established diagnosis of Duchenne Muscular Dystrophy